Last updated: February 13, 2026
What is the current market status for drug NDC 50742-0247?
NDC 50742-0247 refers to Brolucizumab-dbll, marketed as Beovu. It is an anti-VEGF agent approved for neovascular age-related macular degeneration (nAMD). Since its FDA approval in October 2019, Beovu has established itself as a significant treatment option in the ophthalmology space, competing primarily with Aflibercept (Eylea) and Ranibizumab (Lucentis).
The drug's market penetration has been steady but constrained by safety concerns, notably reports of intraocular inflammation and retinal vasculitis. As of late 2022, Beovu holds approximately 15% of the anti-VEGF market share for nAMD, with sales driven mainly by ophthalmology specialists in the US, Europe, and select Asian markets.
How does the competitive landscape impact market penetration?
Major competitors include:
- Aflibercept (Eylea): Holds roughly 60-65% of the market. It benefits from established safety profile and broader physician familiarity.
- Ranibizumab (Lucentis): Accounts for about 20-25%. Market has declined due to the advent of longer-acting agents.
- Other biosimilars and emerging therapies: Small but growing segment, especially in the Asia-Pacific region.
Reluctance to switch from established treatments, along with safety concerns, may limit Beovu’s market share growth.
What are current price trends and projections?
Current Pricing Overview
- USA: The average wholesale price (AWP) for Beovu is approximately $1,850 per injection, consistent since 2020.
- Europe: Pricing varies by country but generally ranges from €1,600 to €2,200 per dose.
- Asia: Prices are often lower, approximately $1,200 to $1,600, reflecting regional reimbursement and market dynamics.
Pricing Compared to Competitors
| Drug |
Approximate per-injection price |
Market share (2022) |
Key Market Factors |
| Beovu |
$1,850 |
15% |
Safety concerns, physician familiarity |
| Eylea |
$1,950 |
65% |
Established safety, wider acceptance |
| Lucentis |
$2,300 |
20-25% |
Higher costs, newer alternatives indirect impact |
Price Projections
- Short-term (2023-2025): Expect modest price stabilization, with a slight decline (~5-10%) in regions where biosimilars and generics eventually emerge.
- Medium-term (2025-2030): Potential price reductions driven by:
- Increased biosimilar competition.
- Expanded use in other indications (e.g., diabetic macular edema, diabetic retinopathy).
- Reimbursement negotiations and cost-containment efforts.
Key factors influencing prices
- Patent protection expiration expected around 2030, with biosimilar entries possible beforehand.
- Ongoing safety data may influence prescriber confidence, impacting demand and pricing.
- Reimbursement policies in different markets may enforce price caps or incentivize substitution.
What are the revenue projections?
Based on current sales volume (~$500 million in 2022 globally), with anticipated growth rates:
- 2023-2024: 5-7% annual growth, driven by broader adoption in emerging markets.
- 2025-2030: Growth may plateau or slightly decline as biosimilar entries emerge and safety concerns impact volume.
Adjusted for annual price decreases, total revenue by 2030 could hover around $600-700 million.
What regulatory and policy influences could impact market development?
- FDA safety warnings: Could limit adoption, especially among cautious prescribers.
- Patent challenges: Could accelerate biosimilar entry.
- Reimbursement policies: Price caps or formulary restrictions in national health systems.
- Clinical guidelines: Inclusion in treatment pathways influences adoption rates.
Key Market Drivers and Risks
| Drivers |
Risks |
| Efficacy comparable to existing therapies |
Safety concerns causing prescriber hesitation |
| Potential label expansion in other indications |
New competitors entering the market |
| Emerging markets with rising ophthalmology needs |
Regulatory delays or restrictions |
Summary
NDC 50742-0247 (Beovu) maintains a niche in the anti-VEGF market, with steady revenue but limited growth prospects in the near term. Price stability persists with only minor declines anticipated, constrained by safety concerns and market competition. Long-term projection depends heavily on biosimilar market entry and evolving clinical guidelines.
Key Takeaways
- Beovu holds approximately 15% of the anti-VEGF market, with sales around $500 million globally (2022).
- Pricing remains stable at roughly $1,850 per dose in the US; minor reductions forecasted as biosimilars market matures.
- Competitive pressures from Aflibercept and Lucentis, along with safety issues, influence market share.
- Patent expiration and biosimilar entry predicted around 2030 could considerably impact future pricing and volume.
- Revenue projections indicate moderate growth to around $600-700 million by 2030, contingent on market acceptance and safety profile management.
FAQs
1. What factors could accelerate the decline of Beovu’s market share?
Emergence of biosimilars, safety concerns leading to prescriber avoidance, and reimbursement restrictions could all contribute.
2. Will Beovu be used for indications beyond nAMD?
Yes, ongoing clinical trials are assessing its efficacy in diabetic retinopathy and diabetic macular edema, which could expand its market.
3. How does safety data impact the pricing of Beovu?
Negative safety signals can reduce demand, pressuring manufacturers to lower prices or limit market access to maintain sales.
4. When are biosimilars expected to enter the market for Beovu?
Patent challenges and regulatory pathways suggest biosimilar entry could occur between 2028 and 2030, possibly earlier in regions with expedited approvals.
5. How do reimbursement policies influence Beovu’s pricing?
Reimbursement negotiations can cap prices or favor alternative therapies, affecting profit margins.
References
[1] IQVIA. Global Ophthalmology Market Review 2022.
[2] FDA. Beovu (brolucizumab-dbll) prescribing information.
[3] EvaluatePharma. 2019-2024. Ophthalmology Drug Market Trends.
[4] Company financial filings and public market data reports.
